Eli Lilly announces positive results from phase 3 ATTAIN-1 trial of orforglipron, an oral GLP-1 receptor agonist to treat obesity: Indianapolis Friday, August 8, 2025, 09:00 Hrs [ ...

In July 2025 alone, Wegovy clocked Rs 7 crore in sales with around 5,000 injections, while Mounjaro posted Rs 47 crore in ...

Recently released results from a clinical trial on orforglipron show that the oral medication can cause impressive weight ...

ATTAIN-1 is the second trial this year to show positive results with once-daily orforglipron, with best results seen at the ...

In Oklahoma, approximately 405,800 adults have diabetes, and every year, about 26,000 adults in the state are diagnosed with ...

Orforglipron showed clinically meaningful results at 72 weeks, after three doses, in a pool of more than 3000 adults.

An experimental once-daily pill to treat obesity can help people lose a significant amount of weight, according to new data ...

Orforglipron led to 12.4% weight loss after 72 weeks while Novo Nordisk’s oral therapy showed a 13.6% drop in weight.

A considerable proportion of adolescents and young adults eligible for glucagon-like peptide 1 receptor agonists (GLP-1 RAs) are uninsured, and many young adults do not have a routine place for health ...

US pharma major Eli Lilly’s shares plunged more than 14% to $630.61 after it announced what was seen by the market ...

The pioneering Danish drugmaker was once the most valuable company in Europe, but analysts say a number of missteps reversed ...